OSI Pharmaceuticals, Inc.
<i>A Wholly-Owned Subsidiary of Astellas US LLC</b
One Bioscience Park Drive
Farmingdale
New York
11735
United States
Tel: 631-962-2000
Fax: 631-752-3880
Website: http://us.astellas.com/
About OSI Pharmaceuticals, Inc.
About OSI Pharmaceuticals
OSI Pharmaceuticals, acquired by Astellas Pharma Inc. in 2010, is a leading biotechnology company focused on the discovery and development of high-quality, next-generation oncology products to both extend and improve the lives of cancer patients worldwide. The acquisition of OSI is expected to augment Astellas' strong existing franchises in urology and transplantation, expanding the product portfolio and pipeline of the combined company. OSI serves as Astellas’ small molecule research arm and focuses on developing mechanism-based approaches to drug discovery directed at the processes underlying the role of the Epithelial Mesenchymal Transition in the development of cancer. OSI has a balanced pipeline of oncology drug candidates that includes both mechanism-based, gene-targeted therapies focused in the areas of signal transduction and apoptosis and next-generation cytotoxic chemotherapy agents. OSI discovered and developed Tarceva® (erlotinib), a leading cancer medication, and has several prospective new oncology candidates in the R&D pipeline.
For additional information about the company, please visit www.astellas.us.
Company Contact Information
Maribeth Landwehr, Director
Corporate Communications
260 articles about OSI Pharmaceuticals, Inc.
-
Thomas W. Burns, CEO of Glaukos, Joins Avedro’s Board of Directors
7/31/2018
Avedro, Inc. today announced that Thomas W. Burns has been elected to its Board of Directors.
-
Genentech, OSI Pharma to Fork Over $67 Million for Misleading Info About Cancer Drug Efficacy
6/7/2016
-
Astellas Pharma Inc. Shuts Down OSI Pharmaceuticals, Inc., Perseid in Restructuring of R&D Ops, Cuts 200 Jobs
5/15/2013
-
PanOptica, Inc. Appoints Colin Goddard, Former CEO of OSI Pharmaceuticals, Inc., to Board of Directors
4/1/2011
-
AVEO Pharmaceuticals, Inc. to Get $25 Million in Milestone Payments from OSI Pharmaceuticals, Inc.
12/1/2010
-
Astellas Pharma Inc. Keeping 90 OSI Pharmaceuticals, Inc. Jobs on Long Island
10/6/2010
-
OSI Pharmaceuticals, Inc. Announces the Results of its Offer to Purchase its 2% Convertible Notes and a Change in the Expiration Time of its Offer to Purchase its 3% Convertible Notes
7/14/2010
-
OSI Pharmaceuticals, Inc. Announces Occurrence of a Fundamental Change for Convertible Notes
6/18/2010
-
OSI Pharmaceuticals, Inc. Announces Occurrence of a Fundamental Change for Convertible Notes
6/10/2010
-
Astellas Pharma Inc. Completes Acquisition of OSI Pharmaceuticals, Inc.
6/9/2010
-
Astellas Pharma Inc. Announces Successful Completion of Tender Offer for Shares of OSI Pharmaceuticals, Inc.
6/8/2010
-
Astellas Pharma Inc. Gets 87% of OSI Pharmaceuticals, Inc. Shares in Sweetened Bid
6/3/2010
-
Expiration Date of OSI Pharmaceuticals, Inc. Offer Extended to June 2, 2010
5/17/2010
-
Astellas Pharma Inc. Buys OSI Pharmaceuticals, Inc. for $4 Billion in Cancer Push
5/17/2010
-
OSI Pharmaceuticals, Inc. Announces That It's Partner Roche Has Received Approval For Tarceva(R) in the European Union for Maintenance Use in Advanced Non-Small Cell Lung Cancer
4/29/2010
-
OSI Pharmaceuticals, Inc. Announces That "RADIANT", an International Phase III Tarceva Adjuvant Trial in Non-Small Cell Lung Cancer, Completes Enrollment
4/26/2010
-
Astellas Pharma Inc. Extends OSI Pharmaceuticals, Inc. Offer, Again
4/23/2010
-
Roche And OSI Pharmaceuticals, Inc.'s Tarceva Gains Unexpected Approval – Datamonitor Comment
4/20/2010
-
Roche, OSI Pharmaceuticals, Inc. Win U.S. Approval for Wider Tarceva Use
4/19/2010
-
Astellas Pharma Inc.: Won't Raise OSI Pharmaceuticals, Inc. Bid on FDA Move Alone
4/19/2010